- Trials with a EudraCT protocol (13)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
13 result(s) found for: tirzepatide.
Displaying page 1 of 1.
| EudraCT Number: 2021-003612-31 | Sponsor Protocol Number: I8F-MC-GPGV | Start Date*: 2022-08-16 |
| Sponsor Name:ELI LILLY & COMPANY, LILLY CORPORATE CENTER | ||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study with an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adol... | ||
| Medical condition: Type 2 Diabetes Mellitus (T2DM) | ||
| Disease: | ||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
| Trial protocol: IT (Completed) FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2019-002735-28 | Sponsor Protocol Number: I8F-MC-GPGN | Start Date*: 2020-03-30 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT) | |||||||||||||
| Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Trial now transitioned) HU (Trial now transitioned) DE (Ongoing) SK (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) NL (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2024-000081-22 | Sponsor Protocol Number: I8F-MC-GPHV | Start Date*: 2024-03-07 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Safety, Tolerability and Pharmacokinetic Study of Tirzepatide for the Treatment of Pediatric Participants (6 years to 11 years) with Obesity. | |||||||||||||
| Medical condition: Weight management | |||||||||||||
|
|||||||||||||
| Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: Outside EU/EEA | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2022-003853-70 | Sponsor Protocol Number: PNRR-MR1-2022-12375914 | Start Date*: 2023-05-02 | |||||||||||||||||||||
| Sponsor Name:OSPEDALE SAN RAFFAELE | |||||||||||||||||||||||
| Full Title: Towards a personalized precision medicine in rare disease: tirzepatide (a dual glucoseĀ dependent insulinotropic polypeptide and glucagon-like peptide-I receptor agonist) monotherapy in patients wi... | |||||||||||||||||||||||
| Medical condition: Wolfram syndrome type 1 | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: IT (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2019-001550-26 | Sponsor Protocol Number: I8F-MC-GPHR | Start Date*: 2020-01-23 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide versus Placebo in Patients with Nonalcoholic Steatohepatitis (NASH) | |||||||||||||
| Medical condition: Nonalcoholic Steatohepatitis (NASH) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) ES (Ongoing) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-000284-23 | Sponsor Protocol Number: I8F-MC-GPHD | Start Date*: 2020-11-03 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly versus Insulin Lispro (U100) Three Times Daily in Participants with Type 2 Diabetes Inadequat... | |||||||||||||
| Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) HU (Completed) CZ (Completed) SK (Completed) GR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2019-000860-99 | Sponsor Protocol Number: I8F-MC-GPGI | Start Date*: 2019-08-16 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide versus Placebo in Patients with Type 2 Diabetes Inadequately Controlled on Insulin Glargine with or wit... | |||||||||||||
| Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SK (Completed) CZ (Completed) DE (Completed) PL (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-005273-47 | Sponsor Protocol Number: I8F-MC-GPIG | Start Date*: 2022-11-21 | ||||||||||||||||
| Sponsor Name:Eli Lilly and Company | ||||||||||||||||||
| Full Title: Tirzepatide Study of Renal Function in People with Overweight or Obesity and Chronic Kidney Disease with or without Type 2 Diabetes: Focus on Kidney Hypoxia in Relation to Fatty Kidney Disease usin... | ||||||||||||||||||
| Medical condition: Obesity and Chronic Kidney disease | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2018-003422-84 | Sponsor Protocol Number: I8F-MC-GPGH | Start Date*: 2019-04-05 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes | |||||||||||||
| Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) AT (Completed) HU (Completed) PL (Completed) ES (Completed) IT (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-004422-29 | Sponsor Protocol Number: I8F-MC-GPGL(b) | Start Date*: 2019-07-26 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Phase 3, Randomized, Open-Label Trial Comparing Efficacy and Safety of Tirzepatide versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients with Type 2 Diabetes (SURPASS-2) | |||||||||||||
| Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2018-002618-11 | Sponsor Protocol Number: I8F-MC-GPGM | Start Date*: 2019-05-06 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: Efficacy and Safety of LY3298176 Once Weekly versus Insulin Glargine in Patients with Type 2 Diabetes and Increased Cardiovascular Risk | |||||||||||||
| Medical condition: Diabetes Mellitus, Type 2 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GR (Completed) ES (Completed) PL (Completed) RO (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-004552-41 | Sponsor Protocol Number: I8F-MC-GPI2 | Start Date*: 2022-09-14 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants who have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Tria... | |||||||||||||
| Medical condition: Obstructive sleep apnea | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-004551-16 | Sponsor Protocol Number: I8F-MC-GPI1 | Start Date*: 2022-09-14 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants who have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Tria... | |||||||||||||
| Medical condition: Obstructive sleep apnea | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.